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ABSTRAK
Aloimunisasi sel darah merah ditakrifkan sebagai pembentukan antibodi di dalam 
respons kepada antigen asing sel merah melalui proses transfusi atau mengandung. 
Di kalangan wanita hamil yang tidak mempunyai sejarah transfusi darah, mereka 
boleh mengalami aloimunisasi pada kehamilan yang lalu atau semasa disebabkan 
oleh kehadiran antigen sel merah bapa yang diwarisi kepada janin. Kajian ini 
bertujuan untuk menentukan prevalens aloimunisasi sel darah merah di kalangan 
wanita hamil tanpa sejarah transfusi darah di PPUKM dan juga untuk mengaitkan 
kelazimannya dengan nombor kehamilan dan sejarah komplikasi obstetrik. Ini 
adalah satu kajian keratan rentas di mana 150 wanita hamil telah dipilih secara rawak 
di klinik antenatal PPUKM. Sepuluh ml darah periferal telah diperolehi selepas 
persetujuan diambil dari setiap pesakit. Ujian yang dijalankan ke atas sampel-
sampel darah tersebut termasuk ujian jenis kumpulan darah ABO dan Rh D dan 
saringan antibodi dengan menggunakan teknik ujian antiglobulin tidak langsung. 
Sampel positif terus dikenalpasti untuk pengkhususan antibodi. Dalam kajian kami, 
majoriti (37.3%) daripada wanita adalah primigravida. Aloantibodi sel darah merah 
telah dikesan pada dua daripada 150 (1.3%) pesakit yang kemudiannya dikenalpasti 
sebagai anti-C dan anti-D. Namun tiada seorang pun daripada primigravida yang 
mengalami aloimunisasi. Seorang  wanita dari gravida 2 (2.9%) dan gravida 3 (3.6%) 
didapati positif bagi aloimunisasi. Salah seorang daripada mereka juga mempunyai 
sejarah obstetrik buruk. Kajian ini menunjukkan bahawa kelaziman aloimunisasi 
sel darah merah di kalangan wanita hamil adalah rendah di pusat ini. Walau 
bagaimanapun, ujian saringan bagi aloantibodi sel darah merah perlu disediakan 
untuk mengurangkan komplikasi kepada janin atau ibu yang mungkin timbul akibat 
aloimunisasi sel darah merah.
Kata kunci: antibodi sel merah, aloimunisasi, saringan antibodi.
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ABSTRACT
Red cell alloimmunisation is defined as the development of antibodies in response 
to foreign red cell antigens through transfusion or pregnancy. In pregnant women 
even without the history of previous blood transfusion, this is possible through 
previous or current pregnancy with the presence of paternal red cell antigen 
inherited by the fetus. This study was aimed to determine the prevalence of red 
cell alloimmunisation among pregnant women without previous history of blood 
transfusion and the association with number of pregnancy and history of obstetric 
complications. This was a cross-sectional study in which 150 pregnant women 
were randomly selected from the antenatal clinic.  Ten mls of peripheral blood 
was obtained for antibody screening using indirect antiglobulin test besides the 
routine antenatal screening. In this study, the majority (37.3%) of the women were 
primigravidae. Red cell alloantibodies were detected in two out of 150 (1.3%) 
patients which were subsequently identified as anti-C and anti-D. However none of 
the primigravida was alloimmunised. One woman of gravida 2 (2.9%) and gravida 
3 (3.6%) each were positive for alloimmunisation.  One of them also had a bad 
obstetric history. This study showed that the prevalence of red cell alloimmunisation 
among pregnant women was low in this centre. Nevertheless, red cell alloantibody 
screening test should be made available to reduce possible complications of 
alloimmunisation in mothers and fetuses. 
Key words: red cell antibody, alloimmunisation, screening, pregnancy
INTRODUCTION
Red cell alloimmunisation in pregnancy 
is an immune disorder due to an 
incompatibility between maternal and 
fetal red blood cell antigens (Roback 
et al. 2008). Haemorrhage of fetal red 
cells into the maternal circulation can 
occur spontaneously during pregnancy 
or with trauma, amniocentesis, 
cordocentesis, abortion, and other 
manipulations. 
 The development of the alloantibody 
is due to the anamnestic response 
(Roback et al. 2008). With the first 
exposure to the foreign antigen, the B 
lymphocyte clones are invoked which 
will result in a moderate production 
of IgM or IgG antibodies. It is the 
secondary exposure that elicits a more 
rapid production of large quantities of 
significant IgG-class antibody which 
can cross the placenta. Destruction 
of the fetal red cells occurs when the 
maternal antibody binds to the fetal 
red cell antigen, causing attachment to 
the Fc receptor of the macrophages in 
the spleen of the fetus and leads to a 
condition called haemolytic disease of 
the fetus and newborn (HDFN) (Denise 
2005 & Roback et al. 2008).The 
newborn infants with HDFN present 
with severe anaemia and jaundice. As 
an example, in a Rh-negative mother 
who is exposed to the fetal Rh-positive 
red cells, the maternal immune system 
will produce anti-D antibodies. In a 
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subsequent pregnancy, these anti-D 
antibodies will cross the placenta 
into the fetal circulation and result in 
haemolysis.
 Approximately 1% of pregnant 
women are found to have clinically 
significant red cell antibodies and there 
are more than 50 red cell antigens 
that can elicit antibodies that have 
been found to cause HDFN (Howard 
et al. 1998 & Moise 2000). Of these, 
the commonest specificity is anti-D, 
although universal introduction of 
routine antenatal anti-D prophylaxis has 
reduced this sensitisation rate (Howard 
et al. 1998 & Moise 2000). However, 
with the introduction of antenatal 
anti-D prophylaxis, there has been 
a significant rise in positive antibody 
screening results, due to the detection 
of the prophylactic anti-D (Howard et 
al. 1998). Other alloimmune antibodies 
that can result in HDFN include other 
Rh (E, e, C, c), Kell (K and k), Duffy (Fya 
and Fyb), Kidd (Jka and Jkb), and MNSs 
(M, N, S and s) (Moise 2000 & Roback 
et al. 2008). Multiparous women and 
mothers with bad obstetric history 
(history of abortion, neonatal death 
and stillbirth) have been found to have 
higher chance of alloimmunisation 
due to multiple exposures to the 
incriminating foreign antigens (Patel et 
al. 2009 & Shanwell et al. 1999).
 According to guidelines issued by 
the British Committee for Standards in 
Haematology, it has been suggested 
that ABO and Rh as well as the 
antibody screening be carried out 
during the antenatal follow up to detect 
the presence of maternal alloantibody. 
Therefore, this study aimed to look 
at the prevalence of development of 
significant alloantibodies in pregnant 
women in this centre and to identify the 
common alloantibodies encountered. 
The knowledge will help reduce the risk 
of complication of haemolytic disease 
of the fetus and newborn and further 
emphasise whether routine antibody 
screening during antenatal check-up is 
justified. 
MATERIALS AND METHODS
This cross-sectional study was done 
on women who had antenatal follow-
up at the antenatal clinic of a tertiary 
hospital. The study was approved by the 
Institutional Review Board and Ethics 
Committee. Women with previous 
history of blood transfusion, women 
with autoimmune hemolytic anaemia 
and those on antibiotics were excluded 
from the study. The patients were 
randomly selected during the period of 
study from January 2012 to April 2012. 
A total of 150 patients’ blood samples 
were subjected to pre-transfusion 
testing which included ABO- and Rh-
grouping and antibody screening. Data 
on age, gravida, parity, past medical and 
obstetrical history were taken. For each 
patient, 5 mls of blood was taken in two 
EDTA tubes. The pretransfusion testing 
were done following the American 
Association of Blood Bank standard 
which consists of identification of the 
recipient and blood sample collected, 
ABO and Rh D typing, and antibody 
screening. The antibody screening 
was done using indirect antiglobulin 
test, performed by gel agglutination 
technique using Diamed gel cards. For 
antibody screening, 3-cell screening 
panels (Diamed ID-Dia cell) were 
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used. The positive results were further 
identified for antibody specificity by the 
Diamed ID-Dia Panel (11 cell panel), 
including the use of enzyme treated 
cells (papain) at 37˚C and anti human 
globulin (AHG) phase.
RESULTS
During the study period, only two 
patients were found to have positive 
antibody screening out of a total 
of 150 patients’ samples, giving an 
incidence of 1.3%. The two positive 
samples were identified as anti-C and 
anti-D. Table 1 shows gravidity versus 
antibody formation. In our study, 56 
samples were primigravidae (37.3%), 
34 women were gravida 2 (22.6%), 
28 women were gravida 3 (18.7%), 19 
women were gravida 4 (12.7%) and 13 
were of gravida 5 or more (8.7%). No 
alloimmunisation was found among 
primigravida, gravida 4 and gravida 
5 or more. The two positive samples 
were from gravida 2 and gravida 3 
with incidences of 2.9% and 3.6% 
respectively. The incidence of antibody 
production was less in normal cases 
(0.87%) than in bad obstetric history 
cases (2.86%) as expected (Table 2).
DISCUSSION
Red cell alloimmunisation can result in 
significant consequences to pregnancy 
outcomes. The production of clinically 
significant anti-D in an Rh negative 
mother has been well established in 
causing severe haemolytic disease of 
the fetus and newborn. However, with 
the current practice of pretransfusion 
testing which includes ABO- and 
Rh-grouping, the possible clinical 
problems associated with anti-D can be 
anticipated and abated early with the 
use of Rh0 (D) immunoglobulin or better 
known as Rhogam.  Nevertheless, there 
are more than 50 red cell antigens which 
are able to elicit antibody production 
in HDFN cases (Howard et al. 1998 & 
Moise 2000).
 Red cell alloimmunisation may also 
pose a significant problem in blood 
transfusion practice. It may result 
in difficulty in finding compatible 
blood for transfusion and could result 
in grave consequences especially 
during emergency. The frequency of 
patients being alloimmunised to non-D 
antibodies has been rising in the past 
decades (Lobo et al. 2006 & Yousuf 
et al. 2012). Another study, Yousuf et 
al. (2012) found that the prevalence 
of positive antibody screening among 
transfusion recipients was 0.76% 
(184/24,263) of pretransfusion samples. 
In this study, the most frequent single 
alloantibody was anti-Mia (29.1%, 
48/165), followed by anti-E (18.6%, 
30/165). Antibody screening, which has 
been implemented in many developed 
countries, help identify and specify 
antibodies in potential recipients 
and thus antigen-negative blood can 
be prepared in the event of blood 
transfusion.
 In pregnancy, however, the incidence 
of red cell alloimmunisation is 1% to 
2% (Howard et al. 1998; Moise 2000; 
Solola et al. 1983 & Weinstein 1982). Lee 
et al. (2003) reported the prevalence of 
clinically significant antibodies among 
Chinese pregnant women to be 0.27%. 
Different ethnic backgrounds may be a 
confounding factor that influences the 
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prevalence of alloantibody production 
in pregnant women. Our study which 
was done on a multiracial population, 
demonstrated a prevalence of 1.3% 
(2/150, one of chinese and one of 
malay ethnicity). Nevertheless, due to 
the small sample size, a bigger study 
is needed to improve the power of 
the study and to differentiate between 
ethnic groups in this country. 
 Red cell alloantibodies detected 
in two (1.3%) patients were identified 
as anti-C and anti-D from a gravida 
2 (2.9%) and gravida 3 (3.6%) 
respectively.  None of the primigravidae 
was alloimmunised.  Each pregnancy 
increases a woman’s risk of fetomaternal 
circulation leak, and therefore increases 
the chance of alloimmunisation. 
 With the same understanding, there 
would be less chance of antibody 
production in women with normal 
pregnancy than in those with bad 
obstetric history. Our data shows the 
incidence for alloimmunisation of 
0.87% (1/115) in women with normal 
obstetric history and 2.86% (1/35) in 
those with bad obstetric history. In 
this study, the gravida 2 had a history 
of an early neonatal death and she 
was positive for anti-C. The other 
patient, who is a gravida 3 at 11 weeks 
gestation, is a Rh negative mother with 
a previous normal obstetric history. 
She was found to be positive for anti-D, 
with a titre of 1:32 (2IU/ml), most 
likely from the Rhogam which was 
administered to her a few days earlier 
due to threatened miscarriage. Passive 
anti-D can be detected for 12 weeks 
or more after anti-D prophylaxis has 
been given (BCSH 2006). Nevertheless, 
in this case active immunisation still 
could not be excluded as it is difficult 
to differentiate anti-D immunoglobulin 
from an immune anti-D.
 From the relatively small sample 
the prevalence for alloimmunisation of 
1.3% among pregnant women in our 
centre was in accordance with other 
studies (Howard et al. 1998; Moise 
2000; Solola et al. 1983 & Weinstein 
1982). The antibodies detected were 
anti-C and anti-D, which belong to 
the Rh group and the incidence of 
red cell alloimmunisation were higher 
in women with bad obstetric history. 
Nevertheless, a bigger sample size 
over a longer study period is needed 
for better demonstration of the true 
prevalence.
Table 1: Gravidity versus Antibody Formation
Gravida
1 2 3 4 ≥5 Total
Total cases 56 34 28 19 13 150
Antibody screening positive 0 1 1 0 0 2
Prevalence of antibody formation (%) 0 2.9 3.6 0 0 1.3
Table 2: Incidence of Antibody 
Formation between Normal and 
Bad Obstetric History
Normal Bad Obst H(x)
Total case 115 35
Positive 
Alloantibody 1 1
% 0.87 2.86
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CONCLUSION
The prevalence of red cell 
alloimmunisation among pregnant 
women in this centre is low, similar to 
other population studies. Nevertheless, 
it is important that red cell antibody 
screening be included as part of 
the antenatal pretransfusion testing 
in accordance with the current 
international guidelines (BCSH 2006), so 
that pregnancies at risk of HDFN can be 
identified and appropriate management 
provided. Where laboratory facilities 
are limited or cost is a factor, selective 
screening of the patients especially 
those with previous bad obstetric 
history and history of blood transfusion 
should be implemented.
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